Format

Send to

Choose Destination
Euro Surveill. 2017 Feb 9;22(6). pii: 30460. doi: 10.2807/1560-7917.ES.2017.22.6.30460.

Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.

Author information

1
British Columbia Centre for Disease Control, Vancouver, Canada.
2
University of British Columbia, Vancouver, Canada.
3
University of Calgary, Calgary, Canada.
4
Public Health Ontario, Toronto, Canada.
5
Institut National de Santé Publique du Québec (National Institute of Health of Quebec), Québec, Canada.
6
Laval University, Quebec, Canada.
7
Centre Hospitalier Universitaire de Québec (University Hospital Centre of Quebec), Québec, Canada.
8
Alberta Provincial Laboratory, Edmonton, Canada.
9
University of Alberta, Edmonton, Canada.
10
University of Toronto, Toronto, Canada.
11
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

Abstract

Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant influenza A(H3N2) viruses considered antigenically matched to the clade 3C.2a vaccine strain. Sequence analysis revealed substantial heterogeneity in emerging 3C.2a1 variants by province and over time. Adjusted VE was 42% (95% confidence interval: 18-59%) overall, with variation by province. Interim virological and VE findings reported here warrant further investigation to inform potential vaccine reformulation.

KEYWORDS:

effectiveness; influenza; influenza virus; influenza-like illness - ILI; vaccine-preventable diseases; vaccines and immunisation

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for European Centre for Disease Prevention and Control (ECDC) Icon for PubMed Central
Loading ...
Support Center